- Nemolizumab reduced pruritus in 58.4% of patients with moderate to severe prurigo nodularis by week 16.
- The phase 3 trial, OLYMPIA 1, assessed the efficacy and safety of nemolizumab in patients with prurigo nodularis.
- Participants receiving nemolizumab showed significant improvements in pruritus and skin lesions compared to the placebo group.
- The primary endpoints included improvement in weekly average PP-NRS and IGA success at week 16.
- Secondary outcomes supported the primary findings, including earlier reductions in pruritus and sleep disturbance by week 4.
Phase 3 Data: Nemolizumab for Prurigo Nodularis Relief
Conexiant
December 12, 2024
